DE60229975D1 - Nf-kb-inhibitoren - Google Patents

Nf-kb-inhibitoren

Info

Publication number
DE60229975D1
DE60229975D1 DE60229975T DE60229975T DE60229975D1 DE 60229975 D1 DE60229975 D1 DE 60229975D1 DE 60229975 T DE60229975 T DE 60229975T DE 60229975 T DE60229975 T DE 60229975T DE 60229975 D1 DE60229975 D1 DE 60229975D1
Authority
DE
Germany
Prior art keywords
kappab
inhibitors
diseases
activation
aminothiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60229975T
Other languages
German (de)
English (en)
Inventor
Zehong Wan
Joelle Lorraine Burgess
James Francis Callahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of DE60229975D1 publication Critical patent/DE60229975D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
DE60229975T 2001-10-04 2002-10-04 Nf-kb-inhibitoren Expired - Lifetime DE60229975D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32697601P 2001-10-04 2001-10-04
PCT/US2002/031902 WO2003029242A1 (en) 2001-10-04 2002-10-04 NF-λB INHIBITORS

Publications (1)

Publication Number Publication Date
DE60229975D1 true DE60229975D1 (de) 2009-01-02

Family

ID=23274589

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60229975T Expired - Lifetime DE60229975D1 (de) 2001-10-04 2002-10-04 Nf-kb-inhibitoren

Country Status (7)

Country Link
US (1) US7166639B2 (enExample)
EP (1) EP1448545B1 (enExample)
JP (1) JP2005506334A (enExample)
AT (1) ATE414697T1 (enExample)
DE (1) DE60229975D1 (enExample)
ES (1) ES2315430T3 (enExample)
WO (1) WO2003029242A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
EP2363396A1 (en) * 2001-06-11 2011-09-07 Virochem Pharma Inc. Thiophene derivatives as antiviral agents for flavivirus infection
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
TW200403991A (en) 2002-04-11 2004-03-16 Smithkline Beecham Corp NF-κb inhibitors
US7375131B2 (en) * 2002-06-06 2008-05-20 Smithklinebeecham Corp. NF-κB inhibitors
SE0202279D0 (sv) * 2002-07-19 2002-07-19 Astrazeneca Ab Novel comppounds
SE0202280D0 (sv) * 2002-07-19 2002-07-19 Astrazeneca Ab Novel compounds
EP1556053A4 (en) 2002-10-31 2006-04-19 Amgen Inc ANTI-INFLAMMATORY AGENTS
WO2004053087A2 (en) * 2002-12-06 2004-06-24 Smithkline Beecham Corporation Nf-κb inhibitors
DE60332482D1 (de) 2002-12-10 2010-06-17 Virochem Pharma Inc Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
ES2314443T3 (es) 2003-08-15 2009-03-16 Astrazeneca Ab Tiofenos sustituidos y sus usos.
WO2005056562A1 (en) * 2003-12-05 2005-06-23 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxylic acid amide compounds as ikk inhibitors
JP2007517843A (ja) * 2004-01-05 2007-07-05 アストラゼネカ アクチボラグ Ｃｈｋ１阻害剤であるチオフェン誘導体
GB0402809D0 (en) * 2004-02-09 2004-03-10 Glaxo Group Ltd Chemical compounds
TW200609237A (en) * 2004-04-12 2006-03-16 Sankyo Co Thienopyridine derivatives
JP5117374B2 (ja) 2005-03-29 2013-01-16 イコス・コーポレイション Ｃｈｋ１阻害に有用なヘテロアリール尿素誘導体
JP5030947B2 (ja) * 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド フラビウイルス感染の治療及び予防のための化合物及び方法
WO2007097981A2 (en) 2006-02-16 2007-08-30 Millennium Pharmaceuticals, Inc. Alpha carbolines and uses thereof
SG176488A1 (en) * 2006-11-15 2011-12-29 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
JP2010006717A (ja) * 2008-06-24 2010-01-14 Kyorin Pharmaceut Co Ltd ジヒドロチエノ［２，３−ｅ］インダゾール化合物
EP2366699B1 (en) 2008-10-02 2013-08-07 Asahi Kasei Pharma Corporation 8-substituted isoquinoline derivative and use thereof
US20100135984A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100135908A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
WO2011077502A1 (ja) * 2009-12-21 2011-06-30 杏林製薬株式会社 ジヒドロチエノ［２，３－ｅ］インダゾール化合物
EP2520292A1 (en) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
EP2898102A4 (en) 2012-09-20 2016-05-18 Univ Emory CLASSIFIERS OF NF-KB-PFADAKTIVIERUNG AND DEVICES AND METHODS OF USE THEREOF
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
WO2019012159A1 (en) 2017-07-14 2019-01-17 Protea Biopharma N.V. METHODS AND MEANS FOR DIAGNOSING AND / OR TREATING A FATIGUE-ASSOCIATED DISEASE
ES3011633T3 (en) 2017-08-31 2025-04-07 Ahammune Biosciences Private Ltd Thiophene compounds, process for synthesis and use thereof for the treatment of autoimmune disorders
CN115161289B (zh) * 2022-03-14 2023-12-05 东南大学 一种用于炎症性疾病治疗的重组腺相关病毒及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468012A (en) * 1973-08-09 1977-03-23 Beecham Group Ltd 2-amino-3-carboxy-thiophene derivatives
DE4039734A1 (de) 1990-12-13 1992-06-17 Basf Ag Substituierte 2-aminothiophene enthaltende herbizide mittel
US6274590B1 (en) * 1993-01-15 2001-08-14 G. D. Searle & Co. Method of treating skin related conditions
DE19642451A1 (de) * 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophencarbonsäureamide
CZ302691B6 (cs) * 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
AU2002211663A1 (en) 2000-10-12 2002-04-22 Smith Kline Beecham Corporation Nf-$g(k)b inhibitors
US6713638B2 (en) * 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
EP2363396A1 (en) * 2001-06-11 2011-09-07 Virochem Pharma Inc. Thiophene derivatives as antiviral agents for flavivirus infection
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US6835745B2 (en) * 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
US7084178B2 (en) * 2003-11-26 2006-08-01 Bristol-Myers Squibb Company Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives

Also Published As

Publication number Publication date
WO2003029242A1 (en) 2003-04-10
ES2315430T3 (es) 2009-04-01
ATE414697T1 (de) 2008-12-15
EP1448545A1 (en) 2004-08-25
EP1448545B1 (en) 2008-11-19
EP1448545A4 (en) 2005-01-12
US7166639B2 (en) 2007-01-23
JP2005506334A (ja) 2005-03-03
US20040192943A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
ATE414697T1 (de) Nf-kb-inhibitoren
SE0203752D0 (sv) New compounds
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
PT1660507E (pt) Inibidores de proteassoma e seus métodos de utilização
ATE414699T1 (de) Inhibitoren von tyrosinkinasen
DE60234778D1 (de) Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis
DE50310980D1 (de) VERWENDUNG VON I kappa B-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE
ATE452642T1 (de) Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
IS7812A (is) Afleiður 4-tetrazólýl-4-fenýlpiperidíns til þess að meðhöndla verk
IL229124A0 (en) Inhibitors with a mutant form of kit
WO2002030353A3 (en) NF-λB INHIBITORS
ATE382048T1 (de) Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen
DE60312997D1 (de) Nf-kb-inhibitoren
DE60322898D1 (de) Verwendung von isoflavonen zur förderung des schlankheitseffekts
DE60329326D1 (de) Tace inhibitoren
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
WO2003086309A3 (en) NF-κB INHIBITORS
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE404203T1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
ATE534380T1 (de) Glepp-1-hemmer bei der behandlung von autoimmun- und/oder entzündungskrankheiten
ATE376416T1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
ATE438859T1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE486598T1 (de) Kinase inhibitoren und deren verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition